cyrilzakka/clinical-trials huggingface dataset:
Medical Assistance in Dying Requests in Pain Clinic

Terminally ill patients often suffer existentially. Terminally ill patients with existential pain may request medical aid in dying. The Canadian government legalized Medical Assistance in Dying (MAiD) for patients unforeseeable deaths. This prospective observational study examined chronic pain clinic patients' MAiD requests. The study assessed the patients' life quality and outcomes.

Adult patients diagnosed with terminal or severe intractable illnesses frequently endure existential distress. Consequently, patients with terminal illnesses who experience existential distress may contemplate or seek medical assistance in dying (MAiD). In March 2021, the Government of Canada implemented amendments to the Criminal Code to authorize Medical Assistance in Dying (MAiD) for individuals whose natural death is not reasonably foreseeable.

This prospective observational study evaluated requests made for MAiD by patients in the chronic pain clinic setting. The study assessed the quality of life and natural outcomes of the patients.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients with chronic pain and disability.

Exclusion Criteria:

* Patients without physical disability.
Oncological Safety of Oncoplastic Breast Surgery in Multicentric Breast Cancer

The purpose of the study is to evaluate Oncological safety of oncoplastic breast surgery in multicentric breast cancer

Breast cancer is the most prevalent cancer in women worldwide, accounting for about 23.8%. Multifocal and multicentric breast tumors are defined as two or more neoplasms separated in one breast. In multifocal tumors, a quarter of the breast is involved while in multicentric tumors, two quarters or more are involved. There is no exact radiological definition, but the distance between the multifocal tumors is less than or equal to 5 cm, whereas the distance between multicentric tumors is 5 cm, or more.

Due to increasingly use of more developed imaging methods such as tomosynthesis, magnetic resonance imaging (MRI) in these patients, we face more MF/MC breast cancer cases. It is seen that MF/MC breast cancer incidence ranges from 6% to 75% in different series.

Breast-conserving surgery (BCS) and radiotherapy have been adopted as the main treatment methods for early breast cancer. However, there are some studies stating that BCS carries risks for local recurrence in patients with MF/MC breast cancer.

Oncoplastic breast conservation (OBC) relies on applying plastic surgery principles within the context of sound oncological resection. Volume-reducing or volume- replacing methods are utilised to optimise postoperative appearances whilst prioritizing negative margin resection, supported by prompt adjuvant therapy. In fact, it is agreed that in cases where more than 20% of the breast tissue must be excised for oncological margin clearance, oncoplastic surgery is likely to require more complex techniques.This may allow larger specimens to be resected than in traditional breast conservation surgery, but with comparable histopathological properties to those who would be offered mastectomy.

Previous work has suggested that as such, OBC should be regarded as a separate entity from breast conservation therapy, and that direct comparison with mastectomy outcomes should be performed to inform decision-making amongst clinicians and with patients when planning for surgery.

Eligibility Criteria:
Inclusion Criteria:

* Female patients with multicentric breast cancer
* Female Patient aged from 18 to 65 years old
* Patients who are fit for general anesthesia.
* Patients who provide a written informed consent.
* Patient who agree to provide short term outcome data and agree to provide contact information to provide contact information

Exclusion Criteria:

* Female patients less than 20 years old
* Stage 4 breast cancer
* Patients who are contraindicated for radiotherapy
* Pregnant patients in first trimester
* Patient with inflammatory carcinoma
The Intra-Aortic Balloon Pumps Insertion Registry on Behalf of the Groupe Des Angioplasticiens de la Région Ouest

Intra-aortic Balloon Pumps (IABP) have been used for roughly 50 years in Critical Care Units, Intensive Care Units, Cath labs as a way to improve systemic and coronary circulation in patients in cardiogenic shock (CS) or at high risk situation as mechanical complications stemming from myocardial infarction (MI), critical coronary stenosis, high-risk PCI, etc. Several papers recently questioned the relevance of this assistance device - namely the IABP-SHOCK II trial in CS and the CRISP-AMI trial in anterior MI without CS - resulting in the downgrading of the recommendation standards of the IABP by medical societies.


Eligibility Criteria:
Inclusion Criteria:

* Males and females at least of 18 of age;
* Undergoing IABP treatment ;
* Subject, relatives or legal guardian signified their non-opposition to participate in the study

Exclusion Criteria:

- IABP insertion in immediate post-intervention period
Heart Safety Study of Ondansetron in Children Receiving Chemotherapy

We will study the effects of ondansetron on measurements of electrical activity in the heart to make sure doses we are using to prevent nausea and vomiting in children receiving chemotherapy are safe.

Children receiving chemotherapy for cancer at the Jimmy Everest Center for Cancer and Blood Disorders in Children also often receive an IV dose of an antiemetic for prophylaxis. The most common antiemetics used are in the family of 5HT3 antagonists, specifically granisetron and ondansetron. Prior to a recent recommendation by the FDA, we have used ondansetron 0.45 mg/kg IV. Based on adult ECG data, the recommended dose of ondansetron has been changed to no greater than 0.15 mg/kg. We have prior studies showing that the bigger dose is better at preventing nausea and vomiting. Therefore we are studying ECG data in patients receiving ondansetron and chemotherapy. Each subject will have two identical cycles of chemotherapy. Prior to the first of the two cycles they will be randomized to receive one of two doses of ondansetron with the first cycle and the other dose with the second cycle. The two doses are the recommended dose of 0.15 mg/kg and a higher dose of 0.3 mg/kg. The dose level the patient receives each cycle will be blinded to the investigator and the subject.

Prior to the first dose of investigational ondansetron, the patient will have an ECG. This ECG will be repeated 30 minutes after the ondansetron is administered and just before chemotherapy administration, and repeated again 30 minutes later. The change in the QTc intervals will be calculated by two independent pediatric cardiologists who are also blinded to the ondansetron dose level received. This process will be repeated with the next course of chemotherapy, with the second dose of ondansetron. Our goal is to see if there is an appreciable difference between the two doses in the QTc interval changes they induce.

Eligibility Criteria:
Inclusion Criteria:

* Age 6 months to 18 years
* Diagnosis of cancer and receiving 2 identical cycles of chemotherapy within 2 months of each other

Exclusion Criteria:

* History of cardiac conduction anomalies, myocardial infarction, structural heart abnormalities (even if repaired)
* Pregnant or of child-bearing age and unwilling to take a pregnancy test
* Potassium or calcium outside of reference range at screening
* Liver enzymes (AST/ALT) or bilirubin \>/= 2 x the upper limit of normal at screening
The Geriatric Acute & Post-acute Care Coordination Program for Fall Prevention in the Emergency Department II

In brief, this K76 study consists of a small open trial to refine the study protocol and train study personnel on study procedures (Aim 1.b.). In Aim 2, we will recruit older adults into a multidisciplinary fall prevention pilot study. Participants will be randomly assigned to usual care with a traditional fall evaluation by an ED clinician (i.e., ED medical staff member) or an intervention. In the intervention, participants will receive an in-ED consultation by a physical therapist and pharmacist to determine reasons for the fall and offer additional education and training. Participants will be provided an Apple Watch to record measures of fitness and falls, if possible, in the following 12 months. Recurrent falls will be measured in twelve-month follow-up.

In order to determine whether a multifactorial fall prevention intervention is feasible, acceptable and may reduce recurrent falls in older adults presenting to the ED after a fall, we will randomize patients to usual care with a traditional fall evaluation by an ED clinician or an intervention. Patients in the intervention arm receive a fall risk assessment and recommendations by a physical therapist. They are also evaluated by a pharmacist and participate in a medication therapy management session with the aim to reduce fall risk increasing medication.

Eligibility Criteria:
Inclusion Criteria:

* Community-dwelling adult (non-institutionalized) 65 years-old or older presenting to ED after a fall
* Fall not due to syncope or external force (i.e., struck by car or assault)
* Fall not due to serious illness (i.e., stroke, acute myocardial infarction)
* Will be discharged to home/assisted living/rehabilitation at completion of ED visit (i.e., not admitted)
* Legally authorized representative able to give informed consent if patient has cognitive impairment on Six Item Screener (score of less than four) either over the phone with witness present or in person
* Must screen or test negative for COVID-19

Exclusion Criteria:

* Unable to give informed consent due to intoxication or altered mental status
* Presence of injuries that prevent mobilization (i.e., pelvic or lower extremity fractures)
* Allergies to any wearable device component
* Unable or unwilling to wear Apple Watch at home (only for periodic study visits)
* Patient has advanced cancer and/or is on hospice care
* Pts coming from SNF or nursing home
* Previously enrolled in GAPcare II Aim1.b
The Effect of Application of TachoSil® in Pancreatoduodenectomy

Fibrinogen/thrombin-coated collagen patch (TachoSil®) is known to have the effect of strengthening tissue anastomosis and promoting suturing to prevent leakage. The purpose of this study is to compare the incidence of pancreatic fistula that is most crucial for surgical outcome and complications in pancreaticoduodenectomy with those of the control group and the TachoSil® apply group.

Patients who were planned to undergo pancreaticoduodenectomy without a history of chronic pancreatitis are enrolled in this open-label, single-center, randomized, single-blind, phase 4 clinical trial.


Eligibility Criteria:
Inclusion Criteria:

* ECOG performance score of 0-2
* Periampulary cancer or borderline tumor that is able to resection on preoperative examination
* Patients without distance metastasis
* Bone marrow function: WBC at least 3,000/mm3 or absolute neutrophil count at least 1,500/mm3, Platelet count at least 125,000/mm3
* Liver function: AST/ALT less than 3 times upper limit of normal
* Kidney function: Creatinine no greater than 1.5 times upper limit of normal
* Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Patients with distant metastases are not eligible
* Recurred periampulary cancer
* Pregnant and breastfeeding women
* Patients with active or uncontrolled infection
* Patients with uncontrolled heart disease
* Patients with moderate or severe comorbidities who are thought to have an impact on quality of life or nutritional status (Liver cirrhosis, chronic kidney failure, heart failure, etc.)
* Patients who underwent other major abdominal organs surgery except for scheduled pancreatoduodenectomy (gastrectomy, colonic resection, etc.)
Triggers of Eating Disorders in Athletes

Over the past 30 years, a high prevalence of eating disorders in sports has been repeatedly documented, yet few preventive measures have been implemented. While most studies explore risk factors through quantitative means, few have investigated how athletes themselves experience the triggering elements in sports and how they perceive these triggers could be better managed. Another persistent question is why some athletes from a given sport and environment develop eating disorders while others do not. This study explore the experienced triggers reported by athletes who have struggled with eating disorders and compare them to the perspectives of athletes without eating disorders from the same environment. The study also aim to gather perceptions from both groups on how eating disorders and body dissatisfaction could be better addressed and prevented in sports.

Thirty years ago a Norwegian publication explored what athletes with eating disorders have experienced as the causes to their condition. Early specialization and sports cultures with early introduction to weighing and weight adjustment, high training volume, and traumatic experiences (body comments, loss of an important coach, family events) were highlighted as key self-perceived causes. This study and findings have been regularly cited and upheld as facts in professional and research literature but have not been further explored or replicated and confirmed since. This may be part of the reason why the sports world has not fully recognized its responsibility for measures despite the prevalence of eating disorders remaining unchanged over these decades. There is a need to continue exploring why some athletes develop eating disorders while others from the same conditions do not. This can be done by building on previous research and knowledge, examining specific personal or situational factors that may constitute an additional vulnerability, and also by considering self-experiences. There is also a need to understand what athletes believe can help reduce body dissatisfaction and eating disorders. This is especially relevant when considering how both the sports world and society have changed over these 30 years. Early specialization in sports, the desire to be a talent at a young age, and the massive influence of social media are factors that may be particularly challenging risk factors. Better knowledge can be used to develop supportive guidelines for sports teams and cultures, necessary rule changes, and in the education, training, and awareness of sports coaches and support staff. Such knowledge is also crucial when the sports world itself is to design the content of a national action plan to prevent body dissatisfaction and eating disorders in sports.

Eligibility Criteria:
Inclusion Criteria:

* previous/current competitive career in sport
* cohort 1: athlete with an/with a history of an eating disorder
* cohort 2: athlete from the same club without an eating disorder

Exclusion Criteria:

* disabled athletes
* not competitive athlete (below Tier 3)
Acupuncture for Plantar Fasciosis in the Primary Care Setting

The purpose of this study is to determine if the addition of acupuncture to a standard of care prescribed exercise program is more effective at improving pain and function in adult patients with plantar fasciosis.

Investigators are studying whether a specific acupuncture protocol, when added to the standard of care treatment, can improve pain and function in adults with plantar fasciosis. Investigators hypothesize that there will be a significant improvement in both pain and functional outcomes, both acutely and over time, in the experimental group compared to the control group. Investigators will measure foot pain immediately prior to treatment (baseline), immediately after the initial treatment and at 2 weeks, 4 weeks, and 3 months. The Foot Function Index Revised short form will be used during the same intervals to evaluate foot function. At 3 months, patients in the non-acupuncture group will cross-over into the acupuncture group if still experiencing pain.

Eligibility Criteria:
THIS STUDY IS BEING CONDUCTED AT A MILITARY INSTALLATION. YOU MUST HAVE MILITARY INSURANCE IN ORDER TO PARTICIPATE IN THIS STUDY.

Inclusion Criteria:

Male and female DoD beneficiaries, age 18 years or older, who have been diagnosed with plantar fasciitis/fasciosis OR Patients meeting criteria of pain in the bottom of the foot/heel with first steps in the morning \& tender to palpation over the medial calcaneal tubercle (where the plantar fascia inserts). Those with acute and chronic diagnoses will be included.

Exclusion Criteria:

* Pregnant
* Absence of leg
* Active cellulitis of lower extremity
* Prior surgery for plantar fasciitis
* Steroid injections in the last 12 weeks for plantar fasciitis; if received in last 12 weeks subjects will be offered to be involved in the study after they have completed a 12 week wash out period.
* Any regenerative therapy to include proliferation therapy or platelet rich plasma therapy in the last 12 weeks for plantar fasciitis; if received in last 12 weeks subject will be offered to be involved in the study after they have completed a 12 week wash out period.
* Botox injections for plantar fasciitis injections in the last 12 weeks for plantar fasciitis; if received in last 12 weeks subject will be offered to be involved in the study after they have completed a 12 week wash out period.
* Use of anticoagulants
* If they have every had any prior acupuncture for plantar fasciitis using the defined KB-2 points
A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT

The goal of this observational study is to assess the reliability and validity of the 9-object MLSDT for evaluation of participants with moderate to severe vision impairment when tested without a wearable low-vision magnifying aid (eGlasses) and then with eGlasses. These results will be compared to ETDRS testing results for the same participants without eGlasses and then with eGlasses. Two cohorts will consist of participants who have vision loss due to STGD or geographic atrophy (GA) due to age-related macular degenerations (AMD). Normally sighted participants will provide a control group.

Here, we aim to test the accuracy and validate the MLSDT using 9 shapes (instead of 3 shapes) as a reliable, standardized and efficient test of functional vision in STGD and GA patients with impaired vision. This includes evaluation of the performance (retest variability and repeatability) of the test(s) based on patients' visual acuity. Furthermore, we will explore descriptive relationships between MLSDT with best-corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study ETDRS) eye chart.

Eligibility Criteria:
Inclusion Criteria:

* Males and females, age ≥ 18 years
* Able to comprehend and give informed consent.
* Able to comply with testing and all protocol tests.
* Eligible for 1 of 3 cohorts listed below:

Cohort 1: Normal-Sighted Participants with clinically normal ocular findings and BCVA range 20/16 to \<20/40 in each eye (ETDRS letter score 71 - 90) Cohort 2: Moderately-Sight Impaired Participants with a BCVA range of 20/40 to \<20/200 (ETDRS letter score of 36 - 70) and a clinical diagnosis of STGD/GA Cohort 3: Severely-Sight Impaired Participants with a BCVA range of 20/200 to 20/800 (ETDRS letter score of 5 - 35) and a clinical diagnosis of advanced STGD/GA

* Clinical diagnosis of STGD for cohorts 2 and 3
* Clinical diagnosis for GA (due to AMD) for cohorts 2 and 3
* Participants who have had anti-VEGF therapy 2 weeks prior to enrollment have to demonstrate 3 months of vision stability and be fluid free on OCT.

Exclusion Criteria:

* Concurrent participation in any interventional clinical trial or receipt of an investigational drug within the previous 6 months

  * Presence of any condition other than STGD or GA from AMD on slit lamp exam or dilated ophthalmoscopy that impairs visual acuity or visual fields e.g., corneal opacity, visually significant cataract or visual field loss in glaucoma
  * No intra-vitreal injection with anti-VEGF two weeks prior to the study
  * Presence of neurological condition that impairs visual acuity
  * Individuals who refuse or are incapable of performing the MLSDT of BCVA tests
  * Individuals with retinal prosthesis (such as ARGUS-II)
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.

This is a Phase 1 dose-finding study of FT538 given in combination with a monoclonal antibody following lymphodepletion in subjects with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Eligibility Criteria:
Inclusion Criteria:

Subjects with locally advanced or metastatic disease who have progressed after at least one line of therapy and diagnosis of one of the following by treatment cohort:

* Cohort A: The following solid tumor malignancies where anti-PD-1/PD-L1 antibodies are approved: cutaneous melanoma, non-small cell/small cell lung cancer, renal cell carcinoma, head and neck squamous cell cancer, microsatellite instability-high/ mismatch repair deficient cancer, gastric cancer, esophageal cancer, cervical cancer, merkel cell carcinoma, endometrial carcinoma, tumor mutation burden-high ≥ 10 mutations/megabase\], cutaneous squamous cell carcinoma, triple-negative breast cancer.
* Cohort B: HER2+ breast cancer that has relapsed or progressed on trastuzumab and progressed on either pertuzumab or HER2-targeting antibody drug conjugate; HER2+ gastric cancer that has relapsed or progressed on trastuzumab-containing therapy; OR any other HER2+ solid tumor having progressed on at least one line of standard-of-care therapy. For any tumor type in this cohort, HER2 status must be documented by a U.S. Food and Administration (FDA) approved test to be ≥2+ IHC or Average HER2 copy number ≥4 signals per cell by in situ hybridization.
* Cohort C: CRC having progressed following prior cetuximab treatment or has KRAS/NRAS mutation; HNSCC having progressed following prior cetuximab.

Capable of giving signed informed consent

Aged \~ 18 years old

Willingness to comply with study procedures and duration

Measurable disease per RECIST v1.1

For subjects with \>1 measurable lesion by RECIST v1.1 that can be safely accessed, willingness to undergo tumor biopsy

Contraceptive use for women and men as defined in the protocol

Exclusion Criteria:

Pregnant or breast-feeding women

ECOG performance status greater than or equal to 2

Evidence of insufficient organ function

Clinically significant cardiovascular disease including left-ventricular ejection fraction \< 45%

Receipt of therapy within 2 weeks prior to Day 1 or five half-lives, whichever is shorter or any investigational therapy within 28 days prior to Day 1

Known active central nervous system (CNS) involvement by malignancy that hasn'thas not remained stable for at least 3 months following effective treatment for CNS disease

Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis or neurodegenerative disease or receipt of medications for these conditions

Currently receiving or likely to require immunosuppressive therapy Active bacterial, fungal, or viral infections including hep B, Hep C or HIV Live vaccine within 6 weeks prior to start of lympho-conditioning

Known allergy to albumin (human) or DMSO